JF
NBIX icon

Jump Financial’s Neurocrine Biosciences NBIX Stock Holding History

Jump Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,824
Closed -$968K – 2227
2025
Q4 		$968K Buy
6,824
+5,011
+276% +$726K 0.01% 983
2025
Q3 		$255K Buy
+1,813
New +$246K ﹤0.01% 1553
2025
Q1 		– Sell
-1,676
Closed -$229K – 1873
2024
Q4 		$229K Sell
1,676
-39,078
-96% -$4.83M ﹤0.01% 1434
2024
Q3 		$4.7M Buy
+40,754
New +$5.59M 0.1% 243
2024
Q1 		– Sell
-16,905
Closed -$2.23M – 2156
2023
Q4 		$2.23M Buy
16,905
+9,023
+114% +$1.04M 0.07% 344
2023
Q3 		$887K Buy
+7,882
New +$830K 0.03% 728
2023
Q2 		– Sell
-10,200
Closed -$1.03M – 2035
2023
Q1 		$1.03M Sell
10,200
-36,122
-78% -$3.76M 0.04% 586
2022
Q4 		$5.53M Sell
46,322
-10,878
-19% -$1.27M 0.29% 78
2022
Q3 		$6.08M Buy
+57,200
New +$5.8M 0.24% 114
2020
Q4 		– Sell
-4,725
Closed -$455K – 1101
2020
Q3 		$455K Buy
+4,725
New +$547K 0.09% 356

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jump Financial's NBIX Position: Q1 2026 in Review

Jump Financial sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 6,824 shares — an estimated $968K sold.

Jump Financial first reported a position in NBIX in Q3 2020 and held it in 10 quarters. The position peaked at $6.08M in Q3 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Jump Financial reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Jump Financial sold 6,824 Neurocrine Biosciences shares in Q1 2026, an estimated $968K.
  • Jump Financial first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 10 quarters.
  • Jump Financial's Neurocrine Biosciences position peaked at $6.08M in Q3 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.